TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -35.81M | -29.89M | -31.66M | -30.14M | -19.61M |
| Total Depreciation and Amortization | 711.00K | 1.03M | 1.12M | 1.25M | 1.28M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.43M | 1.22M | 2.14M | 1.73M | 765.00K |
| Change in Net Operating Assets | 5.26M | -279.00K | 2.18M | -2.11M | -6.20M |
| Cash from Operations | -27.41M | -27.92M | -26.23M | -29.27M | -23.77M |
| Capital Expenditure | -888.00K | -1.37M | -862.00K | -705.00K | -469.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.18M | -80.98M | -32.85M | 36.87M | 2.38M |
| Cash from Investing | 27.29M | -82.35M | -33.72M | 36.16M | 1.91M |
| Total Debt Issued | 32.46M | -- | -- | -- | -- |
| Total Debt Repaid | -17.14M | -- | -- | -- | -- |
| Issuance of Common Stock | 378.00K | 1.23M | 33.32M | 258.00K | 19.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.00M | 0.00 | 128.27M | -- | 0.00 |
| Cash from Financing | 45.69M | 1.23M | 161.59M | 258.00K | 19.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 45.57M | -109.04M | 101.65M | 7.15M | -21.83M |